Interim clinical findings from the first Phase I/IIa trial using autologous-induced pluripotent stem cell (iPSC)-derived ...

Fast, local cryopreservation is a consistent bottleneck for autologous cell therapy developers, even in major cell and gene therapy hubs.

Previously unpublished long-term clinical and imaging findings from participants treated with an induced pluripotent stem ...

In an interview, synthetic biologist Peter Carr explains research on synthetic cells, their potential benefits and hazards, ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

The tumor microenvironment (TME) is one of the most formidable barriers to durable cancer immunotherapy. Far from being a passive bystander, the TME ...